Treatment of dislipemia in patients with metabolic syndrome or diabetes mellitus;Tratamiento de la dislipemia en pacientes con síndrome metabólico o con diabetes mellitus

Medicina Clinica

Volumn 128, Issue 20, 2007, Pages 786-794

  Millán, Jesús ^a,b   Garrido, Juan Antonio ^c   Santos, Pedro González ^d   Masana, Luis ^e   Panisello, Joima ^f   Pintó, Xavier ^g   Ros, Emilio ^h   Carreras, Francesc ⁱ   Civeira, Fernando ^j   Fabiani, Fernando ^k   Fernández Miranda, Consuelo ^l   Lahoz, Carlos ^m  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Universidad de La Coruña   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^f Fundación para El Fomento de la Innovación Industrial FFII   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PHYSICAL ACTIVITY;

EID: 34347392281     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13106338     Document Type: Article

References (66)

1. Hill JO, Bessesen D. What to do about the metabolic syndrome? Arch Intern Med. 2003;163:395-7.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
3. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
4. Grundy SM, Hansen B, Smith S, Cleeman JI, Kahn RA, for conference participants. AHA/NHLBI/ADA conference proceedings. Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation. 2004;109:551-6.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001;285:2486-96.
6. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2725-34.
7. Davidson MH. Emerging therapeutic strategies for the manaagement of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004;93 Suppl:3C-11C.
8. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 2001;24:588-97.
9. González Santos P, González Alegre T, Valdivielso Felices P. HDL, triglicéridos y síndrome de resistencia a la insulina. Clin Invest Arterioscler. 2001;13 Suppl 4:27-34.
10. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-6.
11. Gray RS, Robbins DC, Wang W, Yen JL, Fabsitz RR, Cowan LD, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1997;17:2713-20.
12. Zavaroni I, Dall'Aglio E, Alpi O, Bruschi F, Bonora E, Pezzarossa A, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985;55:259-66.
13. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2 :135-48.
14. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121:1283-8.
15. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients: role of colesterol-ester-transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Tromb Vasc Biol. 1997;17:56-63.
16. Sociedad Española de Arteriosclerosis y Sociedad Española de Diabetes. Dislipemia diabética: documento de consenso de la Sociedad Española de Arteriosclerosis y la Sociedad Española de Diabetes. Clin Invest Arterioscl. 1998;10:55-64.
17. Documento 2005 de Consenso entre varias sociedades científicas sobre pautas de manejo del paciente diabético tipo 2 en España. Rev Clin Esp. 2005;205:23-31.
18. Foro-HDL. Management od dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL Forum. Am J Cardiovasc Drugs. En prensa 2007.
19. Documento de Consenso Obesidad y Riesgo Cardiovascular. Clin Invest Arterioscl. 2003;15:196-233.
20. Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, et al. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention. Recommendations of the HDL Forum. Am J Cardiovasc Drugs. 2004;4:299-314.
21. Davidson JA. Combination lipid-lowerin therapy in diabetes. Current Diabetes Reports. 2003;3:263-8.
22. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:68-71.
23. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28 Suppl 1:4-36.
24. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-32.
25. Chan DC, Watts GF. Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation. 2004;1:3-34.
26. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
27. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-4.
28. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol. 2003;91:29E-39E.
29. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363-72.
30. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pederson O, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
31. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance andlos LDL. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830-5.
32. Esposito K, Marfella R, Ciotola M, Di Palo C, Guigliano F, Giugliano G, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. JAMA. 2004;292:1440-6.
33. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Technical review. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;25:148-98.
34. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-7.
35. Ros E. Dietary cis-monounsaturated fatty acids and metabolic control in type 2 diabetes. Am J Clin Nutr. 2003;78:617S-25S.
36. Mukamal KJ, Jensen MK, Grønbaek M, Stampfer MJ, Manson JE, Pischon T, et al. Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women and men. Circulation. 2005;112:1406-13.
37. Freiberg MS, Samet JH. Alcohol and coronary heart disease. The answer awaits a randomized controlled trial. Circulation. 2005;112:1379-81.
38. National Institutes of Health. Clinical guidelines on the identifcation, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 1998;6 Suppl 2:51-209.
39. Sociedad Española de Arteriosclerosis, Sociedad Española para el Estudio de la Obesidad y Sociedad Española de Endocrinología y Nutrición. Documento de consenso: dislipemia y obesidad. Clin Invest Arterioscl. 1998;10 Supl 1:1-42.
40. Ros E. Dietary cis-monounsaturated fatty acids and metabolic control in type 2 diabetes. Am J Clin Nutr. 2003;78:617S-25S.
41. Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-Gutierrez V, Covas MI, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145:1-11.
42. McManus K, Antinoro L, Sacks F. A randomized controlled trial of a moderate-fat, low-energy diet compared with a low fat, low-energy diet for weight loss in overweight adults. Int J Obes Relat Metab Disord. 2001;25:1503-11.
43. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
44. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109-16.
45. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-8.
46. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632-46.
47. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Technical review. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;25:148-98.
48. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296-308.
49. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-24.
50. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344:3-8.
51. Appel LJ, Sacks FM, Obarzanek E, Swain JF, Miller ER, Conlin PR, et al. Effects of protein, monounsaturated fat and carbohydrate intake on blood pressure and serum lipids. Results of the OmniHeart randomized trial. JAMA. 2005;294:2455-64.
52. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
53. Diabetes Prevention Programme Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
54. Howard BV, Van Horn L, Hsia J, Manson JAE, Stefanick ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern and risk of cardiovascular disease. The Women's Health Initiative randomized controlled dietary modification trial. JAMA. 2006;295:655-66.
55. Stratton IM, Adler AI, Neil HA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
56. Dormandy JA, Charbonnel B, EcKland DJA. Secondary prevention of macrovascular events in patients with type 2 diabetes in PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
57. Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med. 2002;112 Suppl 8A:19-26.
58. Rubins HB, Robins SJ, Collins D. Gemfibrozil for the secondary prevention of coronary Herat disease in men with low levels of high-densitylipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-8.
59. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1829-31.
60. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-9B.
61. Knopp MD. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
62. Vauhan CJ, Gotto AM. Update on statins: 2003. Circulation. 2004;110:886-92.
63. Colhound HM, Betteridge DJ, Durington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
64. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-8.
65. Baigen C, Keech A, Kearney PM, for the Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
66. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-55.